Previous Close | 38.47 |
Open | 38.40 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's Range | 37.27 - 38.60 |
52 Week Range | 23.42 - 38.60 |
Volume | |
Avg. Volume | 886,671 |
Market Cap | 16.307B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.02 |
Earnings Date | Aug 08, 2024 |
Forward Dividend & Yield | 0.45 (1.17%) |
Ex-Dividend Date | May 03, 2024 |
1y Target Est | 37.09 |
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for metastatic breast cancerLaunch expected to be near-term growth driver in US market Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to its reference medicine to be approved by the US Food and Drug Admi
Read about Bausch + Lomb, Sandoz Group and more in the latest Market Talks covering the Health Care sector.